Supriya Lifescience Limited · NSE: SUPRIYA · BSE: 543434
Supriya Lifescience
Quarterly results as filed with BSE. Latest: Q1 FY27 (Apr–Jun 2026), filed 13 Aug 2026.
Q1 FY27 · Standalone
Revenue
189.75₹ Cr
+30.8% vs year ago
Net profit
24.04₹ Cr
−30.9% vs year ago
EPS, basic
2.99₹
−30.8% vs year ago
Net margin
12.7%
−11.3 pts vs year ago
Quarter by quarter
| Quarter | Revenue | YoY | Net profit | YoY | EPS (₹) | Filed |
|---|---|---|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | 189.75 | +30.8% | 24.04 | −30.9% | 2.99 | 13 Aug 2026 |
| Q4 FY26Jan–Mar 2026 | 276.53 | +50.2% | 74.23 | +47.3% | 9.22 | 27 May 2026 |
| Q3 FY26Oct–Dec 2025 | 206.44 | +11.2% | 49.67 | +6.2% | 6.17 | 09 Feb 2026 |
| Q2 FY26Jul–Sep 2025 | 199.83 | +20.3% | 50.43 | +9.3% | 6.27 | 12 Nov 2025 |
| Q1 FY26Apr–Jun 2025 | 145.07 | −9.7% | 34.79 | −22.1% | 4.32 | 10 Sep 2025 |
| Q4 FY25Jan–Mar 2025 | 184.11 | +16.4% | 50.38 | +36.4% | 6.29 | 27 May 2025 |
| Q3 FY25Oct–Dec 2024 | 185.65 | +32.5% | 46.78 | +57.1% | 5.82 | 24 Jan 2025 |
| Q2 FY25Jul–Sep 2024 | 166.10 | +18.6% | 46.15 | +93.2% | 5.71 | 12 Nov 2024 |
| Q1 FY25Apr–Jun 2024 | 160.63 | +21.7% | 44.64 | +56.6% | 5.54 | 24 Aug 2024 |
| Q4 FY24Jan–Mar 2024 | 158.18 | +11.2% | 36.93 | −3.4% | 4.59 | 11 Jun 2024 |
| Q3 FY24Oct–Dec 2023 | 140.07 | +33.2% | 29.79 | +213.0% | 3.70 | 21 Feb 2024 |
| Q2 FY24Jul–Sep 2023 | 140.09 | +24.9% | 23.88 | +41.6% | 2.97 | 22 Nov 2023 |
| Q1 FY24Apr–Jun 2023 | 132.02 | +30.3% | 28.51 | +12.9% | 3.54 | 04 Aug 2023 |
| Q4 FY23Jan–Mar 2023 | 142.27 | −21.5% | 38.23 | −17.3% | 4.75 | 27 May 2023 |
| Q3 FY23Oct–Dec 2022 | 105.14 | −10.1% | 9.52 | −76.0% | 1.18 | 15 Feb 2023 |
| Q2 FY23Jul–Sep 2022 | 112.17 | — | 16.86 | — | 2.10 | 23 Nov 2022 |
| Q1 FY23Apr–Jun 2022 | 101.36 | — | 25.25 | — | 3.14 | 06 Sep 2022 |
| Q4 FY22Jan–Mar 2022 | 181.27 | — | 46.21 | — | 5.74 | 24 May 2022 |
| Q3 FY22Oct–Dec 2021 | 117.00 | — | 39.64 | — | 4.93 | 22 Jan 2022 |
19 filings on record for this company.